|
Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome Clinical research trials and Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome. Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome  Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome
Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome
For Condition: Polyostotic Fibrous Dysplasia
Status: Recruiting
Sponsor(s): National Institute of Dental and Craniofacial Research (NIDCR) ,
Synopsis: This study will investigate how a gene mutation (change in DNA) causes the abnormal bone in fibrous dysplasia-a condition in which areas of normal bone are replaced with a fibrous growth similar to a scar. The bone abnormalities in fibrous dysplasia can occur in a single bone (monostotic fibrous dysplasia), multiple bones (polyostotic fibrous dysplasia), or in McCune Albright syndrome, in which there are associated glandular abnormalities. This study will also examine calcinosis samples that have been surgically removed from patients with juvenile dermatomyositis. Patients who are scheduled to have orthopedic surgery for treatment of polyostotic fibrous dysplasia may participate in this study. A small sample of bone tissue removed during surgery will be given to investigators in this study for research tests. DNA will be extracted from the tissue and tested for the mutation. Investigators will attempt to grow cells from the sample in the laboratory to evaluate them for their ability to grow and make proteins that normal bone cells make. These tests are designed to help scientists understand how the mutation leads to abnormal bone formation and provide information that might lead to better treatments for fibrous dysplasia. Patients with juvenile Dermatomyositis who have a calcinosis sample surgically removed are also eligible for participation. The removed tissues will be examined for their composition and microscopic appearance, to better understand the pathogenesis of dystrophic calcification in this disease.
Details: Polyostotic fibrous dysplasia (PFD) is a sporadic disorder in which multiple sites of bone are replaced by abnormal fibrous tissue. PFD may occur alone or as part of the McCune Albright syndrome (MAS). We have previously identified a somatic activating mutation in the gene encoding the alpha-subunit of Gs, the G protein which mediates the action of hormones that work by increasing intracellular levels of cyclic adenosine monophosphate (cAMP), in affected tissues from patients with PFD and MAS. The objectives of this study are to determine how activating mutations of the Gs alpha-subunit lead to the changes of PFD, and to determine if interventions that block the biochemical effects of the activating mutation in in vitro and in vivo animal model systems could prevent some of the cellular changes characteristic of PFD. To carry out these studies, we plan to obtain pathologic bone tissue from patients with either isolated PFD or PFD in the context of MAS. In one phase of the study, archival pathology specimens of affected bone will be retrospectively analyzed using a variety of immunohistochemical techniques. In the second phase of the study, specimens of affected bone will be obtained prospectively from patients undergoing clinically indicated orthopedic procedures. Specimens will be placed in primary culture, cultured cells will be analyzed for the Gs alpha-subunit activating mutation, and the mutant-bearing cells will be studied by a variety of cell biologic and pharmacologic techniques.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: All patients who are scheduled to have orthopedic surgery for treatment of polyostotic fibrous dysplasia (PFD). Tissue will only be obtained from those patients in whom the procedure is clinically indicated for standard reasons such as treatment of or prevention of fractures, or disfigurement resulting from abnormal growth of facial and/ or skull bones. The diagnosis of PFD will have been established by standard radiologic criteria and in patients with McCune Albright syndrome (MAS), also by the characteristic skin and endocrine manifestations associated with that form of the disease. Patients meeting criteria for juvenile dermatomyositis who undergo surgical removal of calcinosis are eligible. The tissue from surgery would be used in the research study.
Total Enrollment: 999
Location and Contact Information:
National Institute of Dental And Craniofacial Research (NIDCR) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 970055; 97-D-0055
Study Start Date: December 18, 1996
Record last reviewed: November 25, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001973
Other Polyostotic Fibrous Dysplasia Studies:
1. Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
2. Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome
3. Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
4. Screening and Natural History of Patients with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
5. Testolactone for the Treatment of Girls with LHRH Resistant Precocious Puberty
Related Studies:
Other Polyostotic Fibrous Dysplasia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome
|
|
|
|
|
|
|
|
